TCT-841 Baseline characteristics and 3-month outcomes of the EVOLVE Short DAPT Trial: A prospective investigation of abbreviated antiplatelet therapy in high bleeding risk patients treated with a thin-strut bioabsorbable polymer-coated, everolimus-eluting coronary stent

Ajay J. Kirtane,Laura Mauri,Robert C. Stoler,Robert L. Feldman,Franz-Josef Neumann,Loukas Boutis,Naeem Tahirkheli,Ralph Toelg,Islam Othman,Bernardo Stein,Stephan Windecker,Robert W. Yeh,Harold L. Dauerman,Matthew J. Price,Paul Underwood,Dominic J. Allocco,Ian T. Meredith,Dean J. Kereiakes

TCT-841 Baseline characteristics and 3-month outcomes of the EVOLVE Short DAPT Trial: A prospective investigation of abbreviated antiplatelet therapy in high bleeding risk patients treated with a thin-strut bioabsorbable polymer-coated, everolimus-eluting coronary stent

2018

Ajay J. Kirtane
Laura Mauri
Robert C. Stoler
Robert L. Feldman
Franz-Josef Neumann
Loukas Boutis
Naeem Tahirkheli
Ralph Toelg
Islam Othman
Bernardo Stein
Stephan Windecker
Robert W. Yeh
Harold L. Dauerman
Matthew J. Price
Paul Underwood
Dominic J. Allocco
Ian T. Meredith
Dean J. Kereiakes

The SYNERGY stent (Boston Scientific) is a thin-strut platinum chromium metal alloy platform eluting everolimus from an ultrathin abluminal layer of poly(DL-lactide-co-glycolide) bioabsorbable polymer. Drug release and polymer degradation are complete within 4 months of implantation. These design

Keywords:

Everolimus
Stent
Surgery
Coronary stent
Cardiology
Medicine
Internal medicine
drug release
baseline characteristics
bioabsorbable polymer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations